Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the Role of Bone-Modifying Agents (BMA) in Metastatic Breast Cancer. This focused update addressed the new data on intervals between dosing and the role of bone-modifying agents in control of bone pain.
Patients with bone metastases from breast cancer
Intended Guideline Users
Medical oncologists, radiation oncologists, surgical oncologists, oncology nurses, advanced practice providers, patients, patient advocates, caregivers, and oncology pharmacists
- What are the best intervals between dosing of zoledronic acid?
- What is the role of bone-modifying agents in control of pain secondary to bone metastases?